Treatment Options

Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer Bookmark

Article from the National Cancer Institute curated by Editor in Chief George Lundberg, MD, who notes: 

In 2019, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for certain advanced esophageal cancers, depending on testing results. The National Cancer Institute explains here.

Go to full article published by the National Cancer Institute.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

New Standard of Care for Metastatic Renal Cell Carcinoma Bookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

This piece describes huge improvements in the standard of care and outcomes from combo therapy in metastatic renal cell carcinoma.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections Bookmark

Research paper from the Archives of Pathology & Laboratory Medicine curated by Editor in Chief George Lundberg, MD, who notes: 

Plasmacytoid urothelial carcinoma merits special aggressive therapy.

Go to full paper published in the Archives of Pathology & Laboratory Medicine.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Bookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Clinical Impact of New Data in B-Cell Malignancies From 2019 EHA and ICML Bookmark

Continuing medical education course from Clinical Care Options curated by Editor in Chief George Lundberg, MD, who notes: 

Recent research findings can change practices for B-cell malignancies.

Go to educational module at Clinical Care Options (requires free registration).

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Pembrolizumab Plus Lenvatinib Approved for Endometrial Cancer Bookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved a new combination therapy for certain advanced endometrial cancers.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma Bookmark

Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

The FDA has granted accelerated approval for the drug erlofitinib in advanced urothelial malignancies that meet specific criteria.

Go to full article published by the FDA.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers Bookmark

Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.

Go to full article published by Targeted Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Ovarian Cancer: Is This the Beginning of the End? Bookmark

Article from Healio curated by Editor in Chief George Lundberg, MD, who notes: 

This piece discusses recent insights into ovarian cancer, including the fact that this type of cancer sometimes originates in the fallopian tube, and that drugs known as PARP inhibitors show great therapeutic promise.

Go to full article published by Healio.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.